Medical therapy

Recent advances in the medical treatment of urological cancers

This article was originally published here

Front oncol. 2022 Apr 4;12:746922. doi: 10.3389/fonc.2022.746922. eCollection 2022.


The mainstay of medical treatment has been tyrosine kinase (TKI) inhibitors for renal cell cancer (RCC), cytotoxic chemotherapy for urothelial cancer (UC), and androgen deprivation therapy for prostate cancer . These therapeutic modalities still play an important role in these malignancies. However, immune checkpoint inhibitors (ICI) that target PD-1/PD-L1 or CTLA-4 are rapidly being introduced for the treatment of metastatic urological cancers, just as they have been for other malignancies. Currently, the paradigm of medical treatment of patients with metastatic urological cancer is changing dramatically. Accordingly, we need to organize and summarize the new therapeutic tools, which include immune checkpoint inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors, and antibody-drug conjugates (ADCs). This review provides an overview of agents and treatment regimens that have just been launched or will be launched in the near future in Japan. Based on the promising anti-tumor efficacy and manageable safety profiles demonstrated in clinical trials, these new agents and therapies are expected to be rapidly introduced into Japanese clinical practice. Additionally, the newly designed ADC, enfortumab vedotin, which comprises a fully human monoclonal antibody conjugated to an anti-cancer agent Going through a protease-cleavable linker, has just been launched in Japan. In order to offer optimal treatment to our patients, we must fully understand these new therapeutic tools.

PMID:35444946 | PMC:PMC9013821 | DOI:10.3389/fonc.2022.746922